Overview A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors Status: Recruiting Trial end date: 2023-12-01 Target enrollment: Participant gender: Summary This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors. Phase: Phase 1/Phase 2 Details Lead Sponsor: NextCure, Inc.